PIPELINE

ANSHI PIPELINE

Pipeline

THERAPEUTIC FOCUS AREAS

  • OSTEOPOROSIS

    Osteoporosis poses significant challenges, particularly for an aging population. We are dedicated to advancing the field of bone health by developing treatments that not only strengthen bones but also improve overall bone health. Our goal is to empower individuals to lead active and fulfilling lives.

  • OBESITY

    Obesity is a global health crisis, contributing to a range of serious medical conditions. We believe that effective obesity management goes beyond traditional approaches. Anshi is committed to developing novel pharmaceuticals that address the underlying causes of obesity, providing new hope for individuals seeking sustainable weight management solutions.

  • NON-ALCOHOLIC STEATOHEPATITIS (NASH)

    NASH is a silent epidemic, affecting millions of individuals worldwide. It's a complex liver condition with limited treatment options. At Anshi, we are committed to pioneering breakthroughs in NASH therapeutics. Our research and development efforts are dedicated to finding innovative solutions that can halt the progression of this devastating disease.

Pipeline

OUR PIPELINE

Our pipeline of differentiated treatments focuses on chronic diseases with unmet need.

    • Program
    • Indications
    • Preclinical
    • Early Stage Clinical
    • Late Stage Clinical
    • Status
  • Anti-inflammatory
    • ZY0210
    • Pharyngitis,
      Conjunctivitis
    • Submitted
  • Osteoporosis
    • AR231
    • Osteoporosis
    • Lead optimization
  • Metabolic
    • AR342
    • NASH
    • Phase l
    • AR343
    • NASH
    • IND enabling studies
    • AR334
    • Obesity
    • Lead optimization